A 9-week course of trastuzumab as adjuvant therapy in women with hormone receptor–positive, early-stage breast cancer can maintain efficacy and reduce toxicity compared with the standard 1-year course of trastuzumab.
The global phase 3 MONARCH 2 trial showed a significant advantage to adding the CDK4/6 inhibitor abemaciclib to fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer.
CDK4/CDK6 inhibitors are a promising addition to the armamentarium for the treatment of patients with breast cancer. At the 42nd annual meeting of the Oncology Nursing Society, 2 experts discussed the role of these new drugs, and how to factor them into treatment decisions.
Data suggest that greater than one-fourth of patients with estrogen receptor–positive metastatic breast cancer who are treated with an aromatase inhibitor (AI) will develop a mutation in the ESR1 gene, conferring resistance to the AI. Response after AI failure is poor, leading to a search for better therapeutic options.